Vertex Pharmaceuticals Incorporated (VRTX) Q3 2011 Earnings Call October 27, 2011 5:00 pm ET Executives Matthew Emmens - Chairman, Chief Executive Officer and President Peter R. Mueller - Chief Scientific Officer, Executive Vice President of Global Research & Development and Member of the Scientific Advisory Board Nancy J. Wysenski - Chief Commercial Officer and Executive Vice President Michael Partridge - Senior Director of Strategic Communications Robert Kauffman - Ian F. Smith - Chief Financial Officer and Executive Vice President Analysts David Friedman - Morgan Stanley, Research Division Y. Katherine Xu - William Blair & Company L.L.C., Research Division Matthew Roden - UBS Investment Bank, Research Division Mark J. Schoenebaum - ISI Group Inc., Research Division Rachel L. McMinn - BofA Merrill Lynch, Research Division Matthew J. Andrews - Wells Fargo Securities, LLC, Research Division Yaron Werber - Citigroup Inc, Research Division Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division Howard Liang - Leerink Swann LLC, Research Division Geoffrey C Meacham - JP Morgan Chase & Co, Research Division Edward A. Tenthoff - Piper Jaffray Companies, Research Division Terence C. Flynn - Goldman Sachs Group Inc., Research Division Jason Kantor - RBC Capital Markets, LLC, Research Division Philip Nadeau - Cowen and Company, LLC, Research Division PresentationOperator
Good day, ladies and gentlemen, and welcome to the Vertex Pharmaceuticals Inc. Third Quarter 2011 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Michael Partridge. You may begin. Michael Partridge Thank you. Good evening, and welcome to Vertex's Third Quarter 2011 Conference Call. Our commercial team has had great success with the launch of INCIVEK combination treatment for people with genotype 1 chronic hepatitis C. After only 5 months into the launch, we have seen rapid adoption of INCIVEK and increasing penetration into the prescriber base. Matt Emmens will kick things off for us today with comments on the importance of the introduction of INCIVEK, what it means for the future of the company and how we are positioned to just maybe develop and commercialize more new medicines like INCIVEK that can cure or significantly improve the treatment of other serious diseases.